Biotech News

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Inc. (LPCN)Lipocine Inc.2026-06-25 13:46 ESTClinical readout

LPCN (LPCN) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is lpcn.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

LPCNLipocine Inc.2026-06-25 13:46 EST

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

LPCNLipocine Inc.2026-06-25 13:46 EST

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

LPCNLipocine Inc.2026-06-25 13:46 EST

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

LPCNLipocine Inc.2026-06-25 13:46 EST

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

LPCNLipocine Inc.2026-06-25 13:46 EST

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

LPCNLipocine Inc.2026-06-25 13:46 EST

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

LPCNLipocine Inc.2026-06-25 13:46 EST

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

LPCNLipocine Inc.2026-06-25 13:46 EST

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

JAGXJaguar Health2026-06-25 13:46 EST

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

View all latest news

Lipocine Inc.

Lipocine is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

LPCNLipocine Inc.2026-06-26 12:06 EST

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

LPCNLipocine Inc.2026-06-26 12:06 EST

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

LPCNLipocine Inc.2026-06-26 12:06 EST

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

LPCNLipocine Inc.2026-06-26 12:06 EST

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

LPCNLipocine Inc.2026-06-26 12:06 EST

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States